Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) – Analysts at Cantor Fitzgerald decreased their FY2023 earnings per share estimates for shares of Fortress Biotech in a research report issued on Tuesday, May 16th. Cantor Fitzgerald analyst J. Kim now forecasts that the biopharmaceutical company will earn ($1.00) per share for the year, down from their […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Fortress Biotech (NASDAQ:FBIO – Get Rating) is set to announce its earnings results on Friday, May 12th. Fortress Biotech (NASDAQ:FBIO – Get Rating) last issued its quarterly earnings results on Thursday, March 30th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.08). The firm had revenue of […]
Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) has received an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target […]
Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) was the target of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,040,000 shares, a decrease of 8.0% from the March 31st total of 1,130,000 shares. Currently, 1.3% of the shares of the stock are sold […]